Key Market Insights

• Presently, around 60 players worldwide are engaged in the development of novel antibiotics to treat a wide range of clinical conditions; majority of such players are headquartered in North America.
• Close to 70% of the antibiotics have been approved for use in North America, specifically the US; majority of these therapies are quinolones approved for the prevention / treatment of pulmonary infections.
• Currently, 150 clinical-stage antibiotics are being evaluated across different stages of preclinical / clinical development, either as monotherapies or in combination with other drugs to target various types of bacteria.
• Given the rising prevalence of bacterial infections, over 50 stakeholders are focused on the development and evaluation of antibiotics targeting a wide range of gram positive and negative bacterial strains.
• The growing interest in this domain is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to antibiotics have been inked in the last three years.
• Since 2010, over 1,720 clinical trials have been registered to evaluate the safety and efficacy of various antibiotics; majority of these studies have been conducted across various sites in the US.
• Several researchers from renowned universities, currently involved in evaluating efficacy and safety of antibiotics, have emerged as key opinion leaders (KOL); of these, majority of the KOLs are Doctors of Medicine.
• The global antibiotics market is anticipated to grow at a steady pace in coming decade; majority of the share is captured by drugs targeting urinary tract infections.
• The opportunity associated with the global antibiotic market is likely to be well distributed across various types of therapies, routes of administration and key geographical regions.
• Informed estimates of the existing global antibiotics market size and the future opportunity, over the next decade. Based on multiple parameters, such as drug class, mechanism of action, nature of source, target disease indication, type of therapy, routes of administration and key geographical regions. We have provided informed estimates on the evolution of the market for the period 2020-2030.

Table of Contents

1. PREFACE
   1.1. Scope of the Report
   1.2.      Research Methodology
   1.3.      Chapter Outlines
2. EXECUTIVE SUMMARY

2. INTRODUCTION

2.1.      Overview of Antibiotics

2.2.      Characteristics of an Ideal Antibiotic

2.3.      Advantages of Antibiotics

2.4.      Classification of Antibiotics

2.5.      History of Antibiotics

2.6.      Developments in Antibiotics during the Discovery Void

2.7.      Mechanism of Action of Antibiotics

2.8.      Challenges associated with the use of Antibiotics

2.9.      Future Perspectives

3. MARKET LANDSCAPE: APPROVED ANTIBIOTIC GENERICS

3.1.      Approved Antibiotic Generics: Overall Market Landscape

3.2.      Approved Antibiotic Generics: Developer Landscape

4. MARKET LANDSCAPE: APPROVED ANTIBIOTIC BRANDS

4.1.      Approved Antibiotic Brands: Overall Market Landscape

4.2.      Approved Antibiotic Brands: Developer Landscape

5. MARKET LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS

5.1.      Clinical-stage Antibiotics: Overall Market Landscape

5.2.      Clinical-stage Antibiotics: Developer Landscape

6. COMPANY PROFILES

6.1.      Bristol-Myers Squibb

6.1.1.   Company Overview

6.1.2.   Key Executives

6.1.3.   Financial Information

6.1.4.   Product Portfolio

6.1.5.   Recent Developments

6.1.6.   Key Strategies

6.1.7.   Key Focus Areas

6.1.8.   Expert Opinion

6.3.      GlaxoSmithKline

6.4.      Melinta Therapeutics

6.5.      Merck

6.6.      Pfizer

6.7.      Concluding Remarks

7. PARTNERSHIPS AND COLLABORATIONS ANALYSIS

7.1.      Partnership Models

7.2.      Antibiotics: List of Partnerships and Collaborations

8. CLINICAL TRIAL ANALYSIS

8.1.      Analysis Methodology and Key Parameters

8.2.      Antibiotics: Clinical Trial Analysis

9. KEY OPINION LEADERS

9.1.      Assumptions and Key Parameters

9.2.      Methodology

9.3.      Antibiotics: Key Opinion Leaders (KOLs)

10. KEY TRENDS IN ANTIBIOTICS INDUSTRY

10.1.    Impact of COVID-19 on Antibiotics Industry

10.2.    Key Trends in Antibiotics Domain Post-COVID-19

10.3.    Outsourcing Trends

10.4     Drug Pricing Analysis by Drug Class            

11. APPROVED ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS

11.1.    Chapter Overview

11.2.    Methodology and Scoring Criteria

11.3.    Success Protocol Analysis of Recently Approved Antibiotic Brands

11.4.    Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1.    Chapter Overview

12.2.    Methodology and Key Parameters

12.3.    Global Market opportunity, 2023-2035 (USD Billion)

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

To view more details on this report, click on the link:

https://www.rootsanalysis.com/reports/global-antibiotics-market.html

Learn from experts:  do you know about these emerging industry trends?

Patient Recruitment – Key Determinant of Successful Clinical Trials

Exploring AI-based Digital Pathology

Learn from our recently published whitepaper: -

Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Learn more about Roots Analysis consulting services: 

Roots Analysis Consulting - the preferred research partner for global firms

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com